Effect of Drugs on Homocysteine Concentrations

ABSTRACT

Many studies conducted over the last two decades have shown that drug treatment for common medical conditions may have an adverse effect on plasma total homocysteine (tHcy) concentrations. The mechanism for the effects of individual drugs on tHcy concentrations is frequently unknown, as the mechanism of action of the drug may not be established, or the drug is typically administered in combination with other drugs. Some drugs are believed to alter tHcy concentrations by interfering in the metabolism of folate or vitamins B₁₂ or B₆ or by altering renal function, but the underlying mechanisms for the effects on tHcy concentrations of many drugs remains to be discovered. Several widely used drugs, such as lipid-lowering drugs (like fibrates and niacin) or oral hypoglycemic drugs (like metformin), insulin, drugs used in rheumatoid arthritis, and anticonvulsants cause elevated tHcy concentrations. Sex hormones have variable effects on tHcy levels, and N-acetylcysteine lowers tHcy. The mechanisms of action of drugs on tHcy concentrations and strategies to avoid tHcy elevation have been studied. Assuming that the association of tHcy with cardiovascular disease is causal, this article focuses on the adverse effect on tHcy levels of fibrates, statins and niacin, antihypertensive drugs, metformin, methotrexate and sulfasalazine, anticonvulsant drugs, and levodopa and reviews strategies to avoid such effects. The clinical significance, if any, of these adverse effects on plasma tHcy concentrations remains to be determined.

KEYWORDS

Homocysteine - lipid-lowering drugs - methotrexate - diuretics - metformin - antiepileptic drugs - levodopa

REFERENCES

• 1 Ueland P M, Refsum H. Plasma homocysteine, a risk factor for vascular disease: plasma levels in health, disease, and drug therapy.  J Lab Clin Med. 1989;  114 473-501
• 2 Desouza C, Keebler M, McNamara D B, Fonseca V. Drugs affecting homocysteine metabolism: impact on cardiovascular risk.  Drugs. 2002;  62 605-616
• 3 Stergiou G S, Salgami E V. World Health Organization-International Society of Hypertension (WHO-ISH); USA Joint National Committee on Prevention, Detection, Evalutiaon, and Treatment of High Blood Pressure (JNC-7); European Soceity of Hypertension-European Society of Cardiology (ESH-ESC) . New European, American and International guidelines for hypertension management: agreement and disagreement.  Expert Rev Cardiovasc Ther. 2004;  2 359-368
• 4 Nygard O, Vollset S E, Refsum H et al.. Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study.  JAMA. 1995;  274 1526-1533
• 5 Jacques P F, Bostom A G, Wilson P W, Rich S, Rosenberg I H, Selhub J. Determinants of plasma total homocysteine concentration in the Framingham Offspring cohort.  Am J Clin Nutr. 2001;  73 613-621
• 6 Morrow L E, Grimsley E W. Long-term diuretic therapy in hypertensive patients: effects on serum homocysteine, vitamin B6, vitamin B12, and red blood cell folate concentrations.  South Med J. 1999;  92 866-870
• 7 Montenero A S. Drugs producing vitamin deficiencies.  Acta Vitaminol Enzymol. 1980;  2 27-45
• 8 Westphal S, Rading A, Luley C, Dierkes J. Antihypertensive treatment and homocysteine concentrations.  Metabolism. 2003;  52 261-263
• 9 Boushey C J, Beresford S A, Omenn G S, Motulsky A G. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes.  JAMA. 1995;  274 1049-1057
• 10 Mortality after 10 1/2 years for hypertensive participants in the Mltiple Risk Factor Intervention Trial.  Circulation. 1990;  82 1616-1628
• 11 Kezdi P, Kezdi P C, Khamis H J. Diuretic induced long term hemodynamic changes in hypertension. A retrospective study in a MRFIT clinical center.  Clin Exp Hypertens A. 1992;  14 347-365
• 12 Freis E D. The efficacy and safety of diuretics in treating hypertension.  Ann Intern Med. 1995;  122 223-226
• 13 Korkmaz M E, Atar I, Tayfun E et al.. Effects of a beta-blocker and spironolactone on plasma homocysteine levels.  Int J Cardiol. 2003;  88 119-120
• 14 de Lorgeril M, Salen P, Paillard F, Lacan P, Richard G. Lipid-lowering drugs and homocysteine.  Lancet. 1999;  353 209-210
• 15 Dierkes J, Westphal S, Luley C. Serum homocysteine increases after therapy with fenofibrate or bezafibrate.  Lancet. 1999;  354 219-220
• 16 Landray M J, Townend J N, Martin S, Martin U, Wheeler D C. Lipid-lowering drugs and homocysteine.  Lancet. 1999;  353 1974-1975
• 17 Giral P, Bruckert E, Jacob N, Chapman M J, Foglietti M J, Turpin G. Homocysteine and lipid lowering agents. A comparison between atorvastatin and fenofibrate in patients with mixed hyperlipidemia.  Atherosclerosis. 2001;  154 421-427
• 18 Bissonnette R, Treacy E, Rozen R, Boucher B, Cohn J S, Genest Jr J. Fenofibrate raises plasma homocysteine levels in the fasted and fed states.  Atherosclerosis. 2001;  155 455-462
• 19 Jonkers I J, de Man F H, Onkenhout W, van der Laarse A, Smelt A H. Implication of fibrate therapy for homocysteine.  Lancet. 1999;  354 1208
• 20 Harats D, Yodfat O, Doolman R et al.. Homocysteine elevation with fibrates: is it a class effect?.  Isr Med Assoc J. 2001;  3 243-246
• 21 Westphal S, Dierkes J, Luley C. Effects of fenofibrate and gemfibrozil on plasma homocysteine.  Lancet. 2001;  358 39-40
• 22 Melenovsky V, Stulc T, Kozich V et al.. Effect of folic acid on fenofibrate-induced elevation of homocysteine and cysteine.  Am Heart J. 2003;  146 110
• 23 Dierkes J, Westphal S, Kunstmann S, Banditt P, Lossner A, Luley C. Vitamin supplementation can markedly reduce the homocysteine elevation induced by fenofibrate.  Atherosclerosis. 2001;  158 161-164
• 24 Mayer Jr O, Simon J, Holubec L, Pikner R, Subrt I. Fenofibrate-induced hyperhomocysteinemia may be prevented by folate co-administration.  Eur J Clin Pharmacol. 2003;  59 367-371
• 25 Lipscombe J, Bargman J M. Fibrate-induced increase in blood urea and creatinine.  Nephrol Dial Transplant. 2001;  16 1515
• 26 Broeders N, Knoop C, Antoine M, Tielemans C, Abramowicz D. Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent?.  Nephrol Dial Transplant. 2000;  15 1993-1999
• 27 Hottelart C, El Esper N, Rose F, Achard J M, Fournier A. Fenofibrate increases creatininemia by increasing metabolic production of creatinine.  Nephron. 2002;  92 536-541
• 28 Devuyst O, Goffin E, Pirson Y, van Ypersele de Strihou C. Creatinine rise after fibrate therapy in renal graft recipients.  Lancet. 1993;  341 840
• 29 Lipscombe J, Lewis G F, Cattran D, Bargman J M. Deterioration in renal function associated with fibrate therapy.  Clin Nephrol. 2001;  55 39-44
• 30 Randers E, Erlandsen E J. Serum cystatin C as an endogenous marker of the renal function-a review.  Clin Chem Lab Med. 1999;  37 389-395
• 31 Hottelart C, el Esper N, Achard J M, Pruna A, Fournier A. Fenofibrate increases blood creatinine, but does not change the glomerular filtration rate in patients with mild renal insufficiency [in French].  Nephrologie. 1999;  20 41-44
• 32 Deighan C J, Caslake M J, McConnell M, Boulton-Jones J M, Packard C J. Comparative effects of cerivastatin and fenofibrate on the atherogenic lipoprotein phenotype in proteinuric renal disease.  J Am Soc Nephrol. 2001;  12 341-348
• 33 Brattstrom L, Lindgren A, Israelsson B, Andersson A, Hultberg B. Homocysteine and cysteine: determinants of plasma levels in middle-aged and elderly subjects.  J Intern Med. 1994;  236 633-641
• 34 Dierkes J, Jeckel A, Ambrosch A, Westphal S, Luley C, Boeing H. Factors explaining the difference of total homocysteine between men and women in the European Investigation Into Cancer and Nutrition Potsdam study.  Metabolism. 2001;  50 640-645
• 35 Arnadottir M, Hultberg B, Nilsson-Ehle P, Thysell H. The effect of reduced glomerular filtration rate on plasma total homocysteine concentration.  Scand J Clin Lab Invest. 1996;  56 41-46
• 36 Legendre C, Causse E, Chaput E, Salvayre R, Pineau T, Edgar A D. Fenofibrate induces a selective increase of protein-bound homocysteine in rodents: a PPARalpha-mediated effect.  Biochem Biophys Res Commun. 2002;  295 1052-1056
• 37 Luc G, Jacob N, Bouly M, Fruchart J C, Staels B, Giral P. Fenofibrate increases homocystinemia through a PPARalpha-mediated mechanism.  J Cardiovasc Pharmacol. 2004;  43 452-453
• 38 Chambers J C, Ueland P M, Wright M, Dore C J, Refsum H, Kooner J S. Investigation of relationship between reduced, oxidized, and protein-bound homocysteine and vascular endothelial function in healthy human subjects.  Circ Res. 2001;  89 187-192
• 39 Stulc T, Melenovsky V, Grauova B, Kozich V, Ceska R. Folate supplementation prevents plasma homocysteine increase after fenofibrate therapy.  Nutrition. 2001;  17 721-723
• 40 Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. Homocysteine Lowering Trialists' Collaboration.  BMJ. 1998;  316 894-898
• 41 Milionis H J, Papakostas J, Kakafika A, Chasiotis G, Seferiadis K, Elisaf M S. Comparative effects of atorvastatin, simvastatin, and fenofibrate on serum homocysteine levels in patients with primary hyperlipidemia.  J Clin Pharmacol. 2003;  43 825-830
• 42 Malik J, Melenovsky V, Wichterle D et al.. Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial-FAT).  Cardiovasc Res. 2001;  52 290-298
• 43 Sasaki S, Kuwahara N, Kunitomo K et al.. Effects of atorvastatin on oxidized low-density lipoprotein, low-density lipoprotein subfraction distribution, and remnant lipoprotein in patients with mixed hyperlipoproteinemia.  Am J Cardiol. 2002;  89 386-389
• 44 Haak E, Abletshauser C, Weber S et al.. Fluvastatin therapy improves microcirculation in patients with hyperlipidaemia.  Atherosclerosis. 2001;  155 395-401
• 45 Ridker P M, Shih J, Cook T J et al.. Air Force/Texas Coronary Atherosclerosis Prevention Study . (AFCAPS/TexCAPS) Investigators. Plasma homocysteine concentration, statin therapy, and the risk of first acute coronary events.  Circulation. 2002;  105 1776-1779
• 46 MacMahon M, Kirkpatrick C, Cummings C E et al.. A pilot study with simvastatin and folic acid/vitamin B12 in preparation for the Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH).  Nutr Metab Cardiovasc Dis. 2000;  10 195-203
• 47 Capecchi P L, Lazzerini P E, Maccherini M et al.. Pravastatin treatment-associated reduction in plasma homocysteine in heart-transplanted patients.  Transplant Proc. 2002;  34 1273-1274
• 48 Luftjohann D, Sigit J I, Locatelli S, von Bergmann K, Schmidt H H. High-dose simvastin (80 mg/day) decreases plasma concentrations of total homocyst(e)ine in patients with hypercholesteromia.  Atherosclerosis. 2001;  155 265-266
• 49 Basu T K, Mann S. Vitamin B-6 normalizes the altered sulfur amino acid status of rats fed diets containing pharmacological levels of niacin without reducing niacin's hypolipidemic effects.  J Nutr. 1997;  127 117-121
• 50 Garg R, Malinow M, Pettinger M, Upson B, Hunninghake D. Niacin treatment increases plasma homocyst(e)ine levels.  Am Heart J. 1999;  138 1082-1087
• 51 Wang W, Basinger A, Neese R A et al.. Effect of nicotinic acid administration on hepatic very low density lipoprotein-triglyceride production.  Am J Physiol Endocrinol Metab. 2001;  280 E540-E547
• 52 Mudd S H, Poole J R. Labile methyl balances for normal humans on various dietary regimens.  Metabolism. 1975;  24 721-735
• 53 Kubova H, Folbergrova J, Mares P. Seizures induced by homocysteine in rats during ontogenesis.  Epilepsia. 1995;  36 750-756
• 54 Bleich S, Degner D, Bandelow B, von Ahsen N, Ruther E, Kornhuber J. Plasma homocysteine is a predictor of alcohol withdrawal seizures.  Neuroreport. 2000;  11 2749-2752
• 55 Ono H, Sakamoto A, Eguchi T et al.. Plasma total homocysteine concentrations in epileptic patients taking anticonvulsants.  Metabolism. 1997;  46 959-962
• 56 Schwaninger M, Ringleb P, Winter R et al.. Elevated plasma concentrations of homocysteine in antiepileptic drug treatment.  Epilepsia. 1999;  40 345-350
• 57 Yoo J H, Hong S B. A common mutation in the methylenetetrahydrofolate reductase gene is a determinant of hyperhomocysteinemia in epileptic patients receiving anticonvulsants.  Metabolism. 1999;  48 1047-1051
• 58 Apeland T, Mansoor M A, Strandjord R E. Antiepileptic drugs as independent predictors of plasma total homocysteine levels.  Epilepsy Res. 2001;  47 27-35
• 59 Tamura T, Aiso K, Johnston K E, Black L, Faught E. Homocysteine, folate, vitamin B-12 and vitamin B-6 in patients receiving antiepileptic drug monotherapy.  Epilepsy Res. 2000;  40 7-15
• 60 Verrotti A, Pascarella R, Trotta D, Giuva T, Morgese G, Chiarelli F. Hyperhomocysteinemia in children treated with sodium valproate and carbamazepine.  Epilepsy Res. 2000;  41 253-257
• 61 Apeland T, Mansoor M A, Pentieva K, McNulty H, Strandjord R E. Fasting and post-methionine loading concentrations of homocysteine, vitamin B2, and vitamin B6 in patients on antiepileptic drugs.  Clin Chem. 2003;  49 1005-1008
• 62 Apeland T, Mansoor M A, Pentieva K, McNulty H, Seljeflot I, Strandjord R E. The effect of B-vitamins on hyperhomocysteinemia in patients on antiepileptic drugs.  Epilepsy Res. 2002;  51 237-247
• 63 van Ede A E, Laan R FJM, Rood M J et al.. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis.  Arthritis Rheum. 2001;  44 1515-1524
• 64 Refsum H, Ueland P M, Kvinnsland S. Acute and long-term effects of high-dose methotrexate treatment on homocysteine in plasma and urine.  Cancer Res. 1986;  46 5385-5391
• 65 Guttormsen A B, Ueland P M, Lonning P E, Mella O, Refsum H. Kinetics of plasma total homocysteine in patients receiving high-dose methotrexate therapy.  Clin Chem. 1998;  44 1987-1989
• 66 Kishi S, Griener J, Cheng C et al.. Homocysteine, pharmacogenetics, and neurotoxicity in children with leukemia.  J Clin Oncol. 2003;  21 3084-3091
• 67 Krogh Jensen M, Ekelund S, Svendsen L. Folate and homocysteine status and haemolysis in patients treated with sulphasalazine for arthritis.  Scand J Clin Lab Invest. 1996;  56 421-429
• 68 Haagsma C J, Blom H J, van Riel P L et al.. Influence of sulphasalazine, methotrexate, and the combination of both on plasma homocysteine concentrations in patients with rheumatoid arthritis.  Ann Rheum Dis. 1999;  58 79-84
• 69 Roubenoff R, Dellaripa P, Nadeau M R et al.. Abnormal homocysteine metabolism in rheumatoid arthritis.  Arthritis Rheum. 1997;  40 718-722
• 70 Hernanz A, Plaza A, Martin-Mola E, De Miguel E. Increased plasma levels of homocysteine and other thiol compounds in rheumatoid arthritis women.  Clin Biochem. 1999;  32 65-70
• 71 Morgan S L, Baggott J E, Lee J Y, Alarcon G S. Folic acid supplementation prevents deficient blood folate levels and hyperhomocysteinemia during long term, low dose methotrexate therapy for rheumatoid arthritis: implications for cardiovascular disease prevention.  J Rheumatol. 1998;  25 441-446
• 72 van Ede A E, Laan R F, Blom H J et al.. Homocysteine and folate status in methotrexate-treated patients with rheumatoid arthritis.  Rheumatology (Oxford). 2002;  41 658-665
• 73 Slot O. Changes in plasma homocysteine in arthritis patients starting treatment with low-dose methotrexate subsequently supplemented with folic acid.  Scand J Rheumatol. 2001;  30 305-307
• 74 Huemer M, Fodinger M, Huemer C et al.. Hyperhomocysteinemia in children with juvenile idiopathic arthritis is not influenced by methotrexate treatment and folic acid supplementation: a pilot study.  Clin Exp Rheumatol. 2003;  21 249-255
• 75 Kuhn W, Roebroek R, Blom H et al.. Müller T. Elevated plasma levels of homocysteine in Parkinson's disease.  Eur Neurol. 1998;  40 225-227
• 76 Kuhn W, Roebroek R, Blom H, van Oppenraaij D, Müller T. Hyperhomocysteinemia in Parkinson's disease.  J Neurol. 1998;  245 811-812
• 77 Muller T, Werne B, Fowler B, Kuhn W. Nigral endothelial dysfunction, homocysteine, and Parkinson's disease.  Lancet. 1999;  354 126-127
• 78 Muller T, Woitalla D, Hauptmann B, Fowler B, Kuhn W. Decrease of methionine and S-adenosylmethionine and increase of homocysteine in treated patients with Parkinson's disease.  Neurosci Lett. 2001;  308 54-56
• 79 Blandini F, Fancellu R, Martignoni E et al.. Plasma homocysteine and l-dopa metabolism in patients with Parkinson disease.  Clin Chem. 2001;  47 1102-1104
• 80 Muller T, Woitalla D, Fowler B, Kuhn W. 3-OMD and homocysteine plasma levels in parkinsonian patients.  J Neural Transm. 2002;  109 175-179
• 81 Miller J W, Selhub J, Nadeau M R, Thomas C A, Feldman R G, Wolf P A. Effect of L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status.  Neurology. 2003;  60 1125-1129
• 82 Ozkan S, Colak O, Kutlu C, Ertan M, Alatas O. Plasma homocysteine levels in pergolide-treated Parkinson disease patients.  Clin Neuropharmacol. 2004;  27 163-165
• 83 Rogers J D, Sanchez-Saffon A, Frol A B, Diaz-Arrastia R. Elevated plasma homocysteine levels in patients treated with levodopa: association with vascular disease.  Arch Neurol. 2003;  60 59-64
• 84 O'Suilleabhain P E, Sung V, Hernandez C et al.. Elevated plasma homocysteine level in patients with Parkinson disease: motor, affective, and cognitive associations.  Arch Neurol. 2004;  61 865-868
• 85 Muller T, Renger K, Kuhn W. Levodopa-associated increase of homocysteine levels and sural axonal neurodegeneration.  Arch Neurol. 2004;  61 657-660
• 86 Kruman I I, Culmsee C, Chan S L et al.. Homocysteine elicits a DNA damage response in neurons that promotes apoptosis and hypersensitivity to excitotoxicity.  J Neurosci. 2000;  20 6920-6926
• 87 Fassbender K, Mielke O, Hennerici M, Bertsch T. Plasma homocyst(e)ine concentrations in cerebrovascular disease.  Stroke. 1999;  30 2244-2245
• 88 Seshadri S, Beiser A, Selhub J et al.. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease.  N Engl J Med. 2002;  346 476-483
• 89 O'Suilleabhain P, Diaz-Arrastia R. Levodopa elevates homocysteine: is this a problem?.  Arch Neurol. 2004;  61 633-634
• 90 Bailey C J, Path M RC, Turner R C. Metformin.  N Engl J Med. 1996;  334 574-579
• 91 Lord J M, Flight I H, Norman R J. Metformin in polycystic ovary syndrome: systematic review and meta-analysis.  BMJ. 2003;  327 951-953
• 92 Hoogeveen E K, Kostense P J, Jakobs C, Bouter L M, Heine R J, Stehouwer C D. Does metformin increase the serum total homocysteine level in non-insulin-dependent diabetes mellitus?.  J Intern Med. 1997;  242 389-394
• 93 Buysschaert M, Dramais A S, Wallemacq P E, Hermans M P. Hyperhomocysteinemia in type 2 diabetes: relationship to macroangiopathy, nephropathy, and insulin resistance.  Diabetes Care. 2000;  23 1816-1822
• 94 Carlsen S M, Folling I, Grill V, Bjerve K S, Schneede J, Refsum H. Metformin increases total serum homocysteine levels in non-diabetic male patients with coronary heart disease.  Scand J Clin Lab Invest. 1997;  57 521-527
• 95 Wulffele M G, Kooy A, Lehert P et al.. Effects of short-term treatment with metformin on serum concentrations of homocysteine, folate and vitamin B12 in type 2 diabetes mellitus: a randomized, placebo-controlled trial.  J Intern Med. 2003;  254 455-463
• 96 Vrbikova J, Bicikova M, Tallova J, Hill M, Starka L. Homocysteine and steroids levels in metformin treated women with polycystic ovary syndrome.  Exp Clin Endocrinol Diabetes. 2002;  110 74-76
• 97 Aarsand A K, Carlsen S M. Folate administration reduces circulating homocysteine levels in NIDDM patients on long-term metformin treatment.  J Intern Med. 1998;  244 169-174
• 98 Bauman W A, Shaw S, Jayatilleke E, Spungen A M, Herbert V. Increased intake of calcium reverses vitamin B12 malabsorption induced by metformin.  Diabetes Care. 2000;  23 1227-1231
• 99 Andres E, Noel E, Goichot B. Metformin-associated vitamin B12 deficiency.  Arch Intern Med. 2002;  162 2251-2252
• 100 Wouters M G, Moorrees M T, van der Mooren M J et al.. Plasma homocysteine and menopausal status.  Eur J Clin Invest. 1995;  25 801-805
• 101 Andersson A, Hultberg B, Brattstrom L, Isaksson A. Decreased serum homocysteine in pregnancy.  Eur J Clin Chem Clin Biochem. 1992;  30 377-379
• 102 Green T J, Houghton L A, Donovan U, Gibson R S, O'Connor D L. Oral contraceptives did not affect biochemical folate indexes and homocysteine concentrations in adolescent females.  J Am Diet Assoc. 1998;  98 49-55
• 103 Morris M S, Jacques P F, Rosenberg I H et al.. Serum total homocysteine concentration is related to self-reported heart attack or stroke history among men and women in the NHANES III.  J Nutr. 2000;  130 3073-3076
• 104 Steegers-Theunissen R P, Boers G H, Steegers E A, Trijbels F J, Thomas C M, Eskes T K. Effects of sub-50 oral contraceptives on homocysteine metabolism: a preliminary study.  Contraception. 1992;  45 129-139
• 105 Brattstrom L, Israelsson B, Olsson A, Andersson A, Hultberg B. Plasma homocysteine in women on oral oestrogen-containing contraceptives and in men with oestrogen-treated prostatic carcinoma.  Scand J Clin Lab Invest. 1992;  52 283-287
• 106 Smolders R G, de Meer K, Kenemans P, Teerlink T, Jakobs C, van der Mooren M J. Hormone replacement influences homocysteine levels in the methionine-loading test: a randomized placebo controlled trial in postmenopausal women.  Eur J Obstet Gynecol Reprod Biol. 2004;  117 55-59
• 107 Barnabei V M, Phillips T M, Hsia J. Plasma homocysteine in women taking hormone replacement therapy: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial.  J Womens Health Gend Based Med. 1999;  8 1167-1172
• 108 Giltay E J, Verhoef P, Gooren L J, Geleijnse J M, Schouten E G, Stehouwer C D. Oral and transdermal estrogens both lower plasma total homocysteine in male-to-female transsexuals.  Atherosclerosis. 2003;  168 139-146
• 109 Giltay E J, Hoogeveen E K, Elbers J M, Gooren L J, Asscheman H, Stehouwer C D. Effects of sex steroids on plasma total homocysteine levels: a study in transsexual males and females.  J Clin Endocrinol Metab. 1998;  83 550-553
• 110 Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine.  N Engl J Med. 2000;  343 180-184
• 111 Ventura P, Panini R, Pasini M C, Scarpetta G, Salvioli G. N -Acetyl-cysteine reduces homocysteine plasma levels after single intravenous administration by increasing thiols urinary excretion.  Pharmacol Res. 1999;  40 345-350
• 112 Hultberg B, Andersson A, Masson P, Larson M, Tunek A. Plasma homocysteine and thiol compound fractions after oral administration of N-acetylcysteine.  Scand J Clin Lab Invest. 1994;  54 417-422
• 113 Wiklund O, Fager G, Andersson A, Lundstam U, Masson P, Hultberg B. N-acetylcysteine treatment lowers plasma homocysteine but not serum lipoprotein(a) levels.  Atherosclerosis. 1996;  119 99-106
• 114 Ventura P, Panini R, Abbati G, Marchetti G, Salvioli G. Urinary and plasma homocysteine and cysteine levels during prolonged oral N-acetylcysteine therapy.  Pharmacology. 2003;  68 105-114
• 115 Roes E M, Raijmakers M T, Peters W H, Steegers E A. Effects of oral N-acetylcysteine on plasma homocysteine and whole blood glutathione levels in healthy, non-pregnant women.  Clin Chem Lab Med. 2002;  40 496-498
• 116 Dierkes J, Domrose U, Ambrosch A, Bosselmann H P, Neumann K H, Luley C. Response of hyperhomocysteinemia to folic acid supplementation in patients with end-stage renal disease.  Clin Nephrol. 1999;  51 108-115
• 117 Bostom A G, Shemin D, Yoburn D, Fisher D H, Nadeau M R, Selhub J. Lack of effect of oral N-acetylcysteine on the acute dialysis-related lowering of total plasma homocysteine in hemodialysis patients.  Atherosclerosis. 1996;  120 241-244
• 118 Friedman A N, Bostom A G, Laliberty P, Selhub J, Shemin D. The effect of N-acetylcysteine on plasma total homocysteine levels in hemodialysis: a randomized, controlled study.  Am J Kidney Dis. 2003;  41 442-446
• 119 Scholze A, Rinder C, Beige J, Riezler R, Zidek W, Tepel M. Acetylcysteine reduces plasma homocysteine concentration and improves pulse pressure and endothelial function in patients with end-stage renal failure.  Circulation. 2004;  109 369-374
• 120 Dierkes J, Domrose U, Westphal S et al.. Cardiac troponin T predicts mortality in patients with end-stage renal disease.  Circulation. 2000;  102 1964-1969
• 121 Tepel M, van der Giet M, Statz M, Jankowski J, Zidek W. The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial.  Circulation. 2003;  107 992-995
• 122 Ubbink J B, van der Merwe A, Delport R et al.. The effect of a subnormal vitamin B-6 status on homocysteine metabolism.  J Clin Invest. 1996;  98 177-184
• 123 Smulders Y M, de Man A M, Stehouwer C D, Slaats E H. Trimethoprim and fasting plasma homocysteine.  Lancet. 1998;  352 1827-1828